New hope for arthritis sufferers: experimental drug shows promise in Late-Stage trial
NCT ID NCT06276998
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called LNK01001 (Zemprocitinib) in 430 adults with moderate-to-severe rheumatoid arthritis who have not improved with other biologic treatments. Participants receive either the drug or a placebo for 24 weeks, followed by a long-term safety extension. The goal is to reduce joint pain, swelling, and inflammation, but ongoing medication is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China